Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Extensive disease
Gustave Roussy immune score
Lactate dehydrogenase
Neutrophil-to-lymphocyte ratio
Number of metastatic sites
Royal Marsden Hospital prognostic score
Serum albumin
Small cell lung cancer
Journal
World journal of oncology
ISSN: 1920-454X
Titre abrégé: World J Oncol
Pays: Canada
ID NLM: 101564097
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
29
02
2020
accepted:
01
04
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
ppublish
Résumé
The Royal Marsden Hospital prognostic score (RMH score) and the Gustave Roussy immune score (GRIm-score) were developed in order to select more suitable patient for phase I trials. Lactate dehydrogenase (LDH) and serum albumin concentration are common risk factors to these two systems. As the third risk factor, the RMH score and the GRIm-score adopt number of metastatic sites and neutrophil-to-lymphocyte ratio (NLR), respectively. We aimed to investigate whether these two systems are also useful for extensive disease of small cell lung cancer (ED-SCLC). We retrospectively collected 128 patients who had initiated platinum-based chemotherapy at our hospital between September 2007 and March 2018. We divided our patients into low (score 0 - 1) and high (2 - 3) score groups, and compared overall survival (OS) and progression-free survival (PFS) between them. Multivariate Cox proportional hazard analyses found prognostic factors of survival times. Regarding GRIm-score, OS was significantly shorter in high score group than in low score group (median 6.1 vs. 11.4 months, P < 0.01), while no significant difference was observed in PFS (median 4.7 vs. 5.0 months, P = 0.12). Both OS (median 6.9 vs. 12.4 months, P < 0.01) and PFS (median 4.4 vs. 5.4 months, P = 0.01) were significantly shorter in high RMH score group than in low group. Multivariate analyses detected both high GRIm-score (hazard ratio (HR) 1.80, 95% confidence interval (CI) 1.20 - 2.72, P < 0.01) and high RMH score (HR 1.93, 95% CI 1.27 - 2.92, P < 0.01) as independent worse prognostic factors of OS, and then only high RMH score (HR 1.53, 95% CI 1.04 - 2.25, P = 0.03) as independent worse prognostic factor of PFS. Both RMH score and GRIm-score are useful as independent prognostic factors of OS in ED-SCLC. However, only RMH score is an independent prognostic factor of PFS.
Sections du résumé
BACKGROUND
BACKGROUND
The Royal Marsden Hospital prognostic score (RMH score) and the Gustave Roussy immune score (GRIm-score) were developed in order to select more suitable patient for phase I trials. Lactate dehydrogenase (LDH) and serum albumin concentration are common risk factors to these two systems. As the third risk factor, the RMH score and the GRIm-score adopt number of metastatic sites and neutrophil-to-lymphocyte ratio (NLR), respectively. We aimed to investigate whether these two systems are also useful for extensive disease of small cell lung cancer (ED-SCLC).
METHODS
METHODS
We retrospectively collected 128 patients who had initiated platinum-based chemotherapy at our hospital between September 2007 and March 2018. We divided our patients into low (score 0 - 1) and high (2 - 3) score groups, and compared overall survival (OS) and progression-free survival (PFS) between them. Multivariate Cox proportional hazard analyses found prognostic factors of survival times.
RESULTS
RESULTS
Regarding GRIm-score, OS was significantly shorter in high score group than in low score group (median 6.1 vs. 11.4 months, P < 0.01), while no significant difference was observed in PFS (median 4.7 vs. 5.0 months, P = 0.12). Both OS (median 6.9 vs. 12.4 months, P < 0.01) and PFS (median 4.4 vs. 5.4 months, P = 0.01) were significantly shorter in high RMH score group than in low group. Multivariate analyses detected both high GRIm-score (hazard ratio (HR) 1.80, 95% confidence interval (CI) 1.20 - 2.72, P < 0.01) and high RMH score (HR 1.93, 95% CI 1.27 - 2.92, P < 0.01) as independent worse prognostic factors of OS, and then only high RMH score (HR 1.53, 95% CI 1.04 - 2.25, P = 0.03) as independent worse prognostic factor of PFS.
CONCLUSIONS
CONCLUSIONS
Both RMH score and GRIm-score are useful as independent prognostic factors of OS in ED-SCLC. However, only RMH score is an independent prognostic factor of PFS.
Identifiants
pubmed: 32494316
doi: 10.14740/wjon1275
pmc: PMC7239571
doi:
Types de publication
Journal Article
Langues
eng
Pagination
98-105Informations de copyright
Copyright 2020, Minami et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2017 Oct;84:212-218
pubmed: 28826074
Respir Med. 2010 Dec;104(12):1937-42
pubmed: 20719490
Mol Clin Oncol. 2017 Sep;7(3):498-506
pubmed: 28811903
Oncol Res Treat. 2019;42(10):506-515
pubmed: 31336378
PLoS One. 2019 Apr 19;14(4):e0214599
pubmed: 31002722
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Clin Oncol. 2009 Jun 1;27(16):2692-6
pubmed: 19332724
World J Oncol. 2019 Apr;10(2):90-100
pubmed: 31068989
World J Oncol. 2019 Feb;10(1):55-61
pubmed: 30834052
Ann Thorac Cardiovasc Surg. 2009 Feb;15(1):4-9
pubmed: 19262443
Onco Targets Ther. 2016 Sep 20;9:5761-5770
pubmed: 27703374
Br J Cancer. 2014 Jul 29;111(3):452-60
pubmed: 24921916
Acta Med Okayama. 1998 Apr;52(2):105-11
pubmed: 9588226
Lung Cancer. 2000 Nov;30(2):127-34
pubmed: 11086206
Cancer Manag Res. 2018 Nov 21;10:6039-6047
pubmed: 30538553
Br J Cancer. 2008 Mar 25;98(6):1029-33
pubmed: 18349817
Radiother Oncol. 2018 Mar;126(3):499-505
pubmed: 29398150